Lights and shadows on the efficacy of tocilizumab monotherapy in large vessel giant cell arteritis
Rheumatology (Oxford)
.
2024 Jan 4;63(1):6-7.
doi: 10.1093/rheumatology/kead358.
Authors
Miguel Ángel González-Gay
1
2
,
Santos Castañeda
3
,
Elena Heras-Recuero
1
,
Raquel Largo
1
Affiliations
1
Division of Rheumatology, Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Spain.
2
Medicine and Psychiatry Department, Universidad of Cantabria, Santander, Spain.
3
Division of Rheumatology, Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.
PMID:
37458478
DOI:
10.1093/rheumatology/kead358
No abstract available
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use
Giant Cell Arteritis* / drug therapy
Humans
Takayasu Arteritis*
Treatment Outcome
Substances
tocilizumab
Antibodies, Monoclonal, Humanized
Grants and funding
FIS PI22/01263/Instituto de Salud Carlos III
RICORS RD21/0002/0025/Spanish Red de Investigación
FIS PI22/00352/Instituto de Salud Carlos III